Figure 1A




Figure 1B




Figure 2A




Figure 2B




Figure 2C

CAL-1 NFkB-GFP cells (human) were stimulated with CpG2395(1uM) for 6hr in the presence of 0.1uM of inhibitory-ODNs




Figure 2D

CAL-1 NFkB-GFP cells (human) were stimulated with CpG2395(1uM) for 6hr in the presence of inhibitory-ODNs




Figure 3

CAL-1 cells (human) were stimulated with CpG2395(0.4uM) in the presence of inhibitory-ODNs
inhibitor concentration ; 0.4uM>0.13uM>0.04uM




Figure 4

CAL-1 cells (human) were stimulated with CpG2395(0.4uM) in the presence of inhibitory-ODNs.

TNFa production by CpG2395 was evaluated.




Figure 5A




Figure 5B




Figure 6



Human IFNa (pg/ml)
5000
4000
3000
2000
1000
0
Control
(CCT)8
(CCT)9
(CCT)10
(CCT)11
(CCT)12
(CCT)14
(CCT)16

Figure 7A

CAL-1 NFkB-GFP cells (human) were stimulated with Gardiquimod (2ug) for 4hr in the presence of inhibitory-ODNs.




Figure 7B

CAL-1 NFkB-GFP cells were stimulated with CL264 (TLR7 ligand) in the presence of inhibitory-ODNs

